RP Bio Inc.
Financials
Valuation Metrics
RP Bio Inc.'s Market Cap is ₩536B. At end of 2025 it was ₩641B. Ranked #1692 of 2,436 in KR market (top 69%), #1016 of 1,649 on KOSDAQ (top 62%), #186 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 79%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 53.64B KRW | KR#1,692/2,436 Sec#186/234 |
| Revenue | 137.35B KRW | KR#1,220/2,436 Sec#74/234 |
| Net Income | 5.60B KRW | KR#1,086/2,436 Sec#73/234 |
| Total Assets | 164.69B KRW | KR#1,405/2,436 Sec#111/234 |
| Net Assets | 109.32B KRW | KR#1,337/2,436 Sec#107/234 |
| Employees | 493 | KR#498/2,436 Sec#42/234 |
| Value | ||
| P/E | 9.57x | KR#688/2,436 Sec#35/234 |
| P/B | 0.49x | KR#783/2,436 Sec#31/234 |
| PEG | 0.18x | KR#492/2,436 Sec#26/234 |
| P/S | 0.39x | KR#750/2,436 Sec#20/234 |
| EV/EBITDA | 9.88x | KR#594/2,436 Sec#26/234 |
| FCF Yield | 13.56% | KR#500/2,436 Sec#14/234 |
| Profitability | ||
| ROE | 5.12% | KR#981/2,436 Sec#74/234 |
| ROA | 3.40% | KR#892/2,436 Sec#77/234 |
| Op. Margin | 4.15% | KR#1,031/2,436 Sec#81/234 |
| Revenue Growth | 3.34% | KR#1,253/2,436 Sec#116/234 |
| Earnings Growth | 54.27% | KR#549/2,436 Sec#31/234 |
| Financial Health | ||
| Debt Ratio | 150.64% | KR#1,195/2,436 Sec#139/234 |
| Total Debt | 16.00B KRW | KR#1,444/2,436 Sec#125/234 |
| FCF | 7.28B KRW | KR#802/2,436 Sec#50/234 |
| Cash | 13.25B KRW | KR#1,503/2,436 Sec#111/234 |
| Current Ratio | 1.34x | KR#1,439/2,436 Sec#153/234 |
| Net Debt/EBITDA | 0.48x | KR#742/2,436 Sec#50/234 |
| Dividend | ||
| Div. Yield | 0.83% | KR#1,189/2,436 Sec#73/234 |
| Performance | ||
| 1Y Return | 5.45% | KR#610/2,436 Sec#46/234 |
| 1M Return | 11.73% | KR#242/2,436 Sec#15/234 |
| From 52W High | -32.20% | KR#482/2,436 Sec#32/234 |
| 1Y MDD | -36.83% | KR#400/2,436 Sec#29/234 |
| Trading | ||
| Volume | 27,522 shares | KR#1,719/2,436 Sec#173/234 |
| Foreign Own. | 1.98% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 646 KRW | KR#812/2,436 Sec#60/234 |
| BPS | 12,639 KRW | KR#786/2,436 Sec#55/234 |
Company Info
RP Bio, established in 2016 through a spin-off and listed on KOSDAQ in 2022, is the sole domestic company inheriting Dr. RP Scherer's soft capsule manufacturing technology since 1983. The company manufactures and supplies various pharmaceuticals and health functional foods, including soft capsules, holding over 60% of the domestic soft capsule market share. RP Bio maintains long-term collaborations with major pharmaceutical companies, possesses 28 patents, and pursues global market expansion strategies based on its quality competitiveness.